A one, two punch for liver cancer: Anti-angiogenesis with a death receptor agonist

Cancer Biology and Therapy

Volumn 8, Issue 5, 2009, Pages 474-475

  Plastaras, John P ^a,c   Kozak, Kevin R ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Combination therapy; Endostatin; Gene therapy; Hepatocellular carcinoma; Naked DNA; pVAX1; TRAIL

Indexed keywords

ENDOSTATIN; PLASMID DNA; PLASMID VECTOR; PROTEIN MCL 1; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RESEARCH; HUMAN; LIVER CARCINOMA; NONHUMAN; NOTE; TUMOR VASCULARIZATION;

EID: 66149102085     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.5.8261     Document Type: Note

References (8)

1. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New Engl J Med 2009; 360:563-572
2. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nature Reviews 2008; 8:579-591
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390
4. Zhang Y, Qu ZH, Cui M, Guo C, Zhang XM, Ma CH, et al. Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice. Cancer Biology & Therapy 2009; this issue.
5. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-681 (Pubitemid 44403686)
6. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12:66-80.
7. Plastaras JP, Dorsey JF, Carroll K, Kim SH, Birnbaum MJ, El-Deiry WS. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol Ther 2008; 7:2047-2053
8. Aiuti A, Bachoud-Levi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA, et al. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther 2007; 14:1555-1563